Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Diabetes (Type 2) — Weekly Report — October 12, 2026

Home/Health Insights/Diabetes (Type 2) — October 12 – October 19, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Diabetes (Type 2)
Updated Monday · November 16, 2026
Diabetes (Type 2) · October 12 – October 19, 2026

Diabetes (Type 2)
Weekly Report

This week's data 21 new clinical trials registered across 10 countries, with 1,957 trials actively recruiting patients worldwide.
Week of October 12 – October 19, 2026
  • 21 new clinical trials registered across 10 countries.
  • 1,957 trials actively recruiting patients worldwide.
  • Notable trial: Digital Nudges to Improve Heart Health Actions After Community Screening in Malaysia (NADI-MyHeartRisk) (6588 patients).
  • 420 new research papers published.
  • Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 12 – October 19, 2026
New Trials This Week
21.
registered Oct 12–Oct 19
Recruiting Now
1,957
active trials seeking patients
Countries
10
with active trials this week
Papers Published
420
new studies this week
Phase 3 Trials
2
late-stage trials this week
Fig. 01

Trials by country

Count · October 12 – October 19, 2026
Malaysia
4
Turkey (Türkiye)
4
United States
3
Vietnam
3
China
2
Egypt
2
Not specified
1
India
1
Serbia
1
Taiwan
1
0 1 2 3 4
total
Fig. 02

Trials by phase

Distribution · October 12 – October 19, 2026

New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

21 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control Diabetes (Type 2) · Vincentage Pharma Co., Ltd (NCT07872436) Phase 2 Not Yet Recruiting 120 China
02 Prevalence and Predictors of Hypercorticolism in Patients With Difficult to Control Type 2 Diabetes Mellitus Diabetes (Type 2) · Assiut University (NCT07873320) Other Enrolling By Invitation 290 Egypt
03 The Effect of Nutrient Sequencing in Healthy Adults Diabetes (Type 2) · Cornell University (NCT07873437) Other Active Not Recruiting 40 United States
04 Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function Diabetes (Type 2) · Chendu DIAO Pharmaceutical Group CO., LTD. (NCT07877038) Phase 1 Not Yet Recruiting 32 N/A
05 A Study in Type 2 Diabetes Patients Who Are Taking Moderate Dose Insulin, Looking at the Effects of the Medication Luseogliflozin on Risk of Ketoacidosis and Insulin Resistance. Diabetes (Type 2) · Aimi Fadilah Mohamad (NCT07876258) Phase 3 Completed 40 Malaysia
06 Maternal Glucose, Cortisol, and Neonatal Outcomes With and Without GDM Diabetes (Type 2) · Hanoi Medical University (NCT07870629) Other Not Yet Recruiting 126 Vietnam
07 Effects of Progressive Muscle Relaxation on Anxiety, Depression, and Quality of Life in Adults With Type 2 Diabetes Diabetes (Type 2) · Gul Dural (NCT07876401) Other Completed 80 Turkey (Türkiye)
08 Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets Diabetes (Type 2) · Humanis Saglık Anonim Sirketi (NCT07872358) Phase 1 Completed 36 India
09 Effectiveness of a Multimodal Cognitive Rehabilitation Protocol Combined With Mechanical Periodontal Therapy in Diabetic Patients With Cognitive Impairment Diabetes (Type 2) · Emad Eldin Mohamed (NCT07870291) Other Active Not Recruiting 105 Egypt
10 Effects of High-Intensity Interval Training and Exercise Snacking on Glycemic Control and Cardiorespiratory Fitness in Adults With Type 2 Diabetes Mellitus Diabetes (Type 2) · University of Nis (NCT07876180) Other Completed 60 Serbia
11 Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing Diabetes (Type 2) · BREGO Life Sciences (NCT07877948) Other Recruiting 100 Malaysia
12 Wearable NH₃ Sensor for Remote Non-invasive Monitoring and Diagnosis of Diabetic Kidney Disease Diabetes (Type 2) · Shanghai Pudong Hospital (NCT07875010) Other Active Not Recruiting 380 China
13 Pancreas Transplant Alone in Uremia and Non-uremia Patients Diabetes (Type 2) · Taipei Veterans General Hospital, Taiwan (NCT07872800) Other Completed 184 Taiwan
14 Silymarin Effects on Fatty Liver in Type 2 Diabetics Diabetes (Type 2) · University of Mosul (NCT07871370) Other Completed 120 Iraq
15 Effects of a Specialized Diabetes and Heart Clinic and Detection of Unrecognized Heart Failure in People With Type 2 Diabetes and Cardiovascular Disease Diabetes (Type 2) · Odense University Hospital (NCT07878325) Other Recruiting 375 Denmark
16 Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight Diabetes (Type 2) · Amgen (NCT07871409) Phase 3 Not Yet Recruiting 230 United States
17 Digital Nudges to Improve Heart Health Actions After Community Screening in Malaysia (NADI-MyHeartRisk) Diabetes (Type 2) · Cardiovascular Advancement and Research Excellence Institute (NCT07879144) Other Not Yet Recruiting 6,588 Malaysia
18 Sleep Quality, Adiposity and Diet Quality Diabetes (Type 2) · Izmir Democracy University (NCT07870122) Other Not Yet Recruiting 209 Turkey (Türkiye)
19 Randomized Transition to Gla-300 in Pediatric Type 1 Diabetes: CGM-Derived Outcomes Diabetes (Type 2) · Marmara University (NCT07872475) Phase 4 Completed 71 Turkey (Türkiye)
20 Maternal and Cord Blood MST1 Levels in Gestational Diabetes Mellitus Diabetes (Type 2) · Samsun University (NCT07878455) Other Active Not Recruiting 75 Turkey (Türkiye)
21 Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs Diabetes (Type 2) · Weill Medical College of Cornell University (NCT07878806) Other Not Yet Recruiting 50 United States
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
metformin Diarrhoea 2,240
semaglutide Nausea 2,963
sitagliptin Nausea 330
empagliflozin Nausea 823
insulin glargine Off Label Use 4,775

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

420 papers

Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Targeting the Gut Microbiota-Metabolism Axis: Novel Pharmacological Mechanisms and Translational Application Strategies for Oral Antidiabetic Drugs. Yang R et al. 10.1002/med.70117
View abstract

Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic metabolic disease worldwide, and the clinical prevention and control situation is severe. Although the various antidiabetic drugs currently in clinical use can lower blood glucose levels through different mechanisms, there are significant differences in efficacy among individuals. Existing evidence suggests that differences in gut microbiota (GM) composition and metabolic function may be one of the key factors contributing to the heterogeneity in drug efficacy. Based on this, this review describes the physiological and pathological mechanisms of the GM-metabolism axis and systematically reviews the modulatory effects of different classes of antidiabetic drugs on this axis and their underlying mechanisms. Available studies suggest that metformin, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors (DPP-4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), thiazolidinediones (TZDs), and oral glucagon-like peptide-1 receptor agonists (GLP-1RAs) may differentially affect GM composition and/or microbial metabolites, including short-chain fatty acids (SCFAs), branched-chain amino acids (BCAAs), and bile acids. These alterations may be associated with glucose homeostasis and insulin resistance through pathways involving GPR41/43, HDACs, AMPK, mTORC1/S6K1, FXR-FGF15/19, and TGR5-GLP-1 signaling. By integrating clinical and mechanistic evidence, this review highlights the potential contribution of the GM-metabolism axis to the glucose-lowering effects of antidiabetic drugs. However, the quantity and confidence of evidence vary substantially across drug classes, and causal and clinical relevance requires further validation. These findings provide a basis for future research on personalized interventions for T2DM characterized by SCFA-producing bacterial deficiency, BCAA overload, or dysregulated bile acid metabolism.

Medicinal research reviews 2026 Oct 18 PubMed
02 From Structural Modification to Diverse Pharmacological Activities: Recent Advances and Future Perspectives of Bile Acids. Zhu H et al. 10.1002/med.70116
View abstract

Bile acids (BAs) are amphiphilic steroid acids that exert a broad range of physiological effects-including the regulation of metabolism, immune responses, and inflammatory processes-through activation of specific receptors such as the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor 1 (TGR5). The gut microbiota plays a critical role in BA metabolism, and alterations in the BA pool have been closely linked to various metabolic disorders, including nonalcoholic fatty liver disease and type 2 diabetes. Consequently, targeting BA signaling pathways offers a novel mechanistic perspective for the prevention and treatment of these metabolic and inflammatory diseases. With growing insight into the biological functions of BAs, the development of BA-based therapeutics and their structural derivatives is emerging as a promising strategy for the management of metabolic diseases.

Medicinal research reviews 2026 Oct 18 PubMed
03 Successful management of high-risk proliferative diabetic retinopathy during pregnancy with intravitreal faricimab. Scallon S et al. 10.1093/omcr/omag195
View abstract

Management of proliferative diabetic retinopathy during pregnancy requires balancing maternal vision preservation against uncertain fetal risks associated with intravitreal anti-vascular endothelial growth factor therapy. We report a 27-year-old woman with a chronic type 1 diabetes mellitus who presented at 28 weeks and 1 day of gestation with high-risk proliferative diabetic retinopathy and dense vitreous hemorrhage in the left eye, precluding panretinal photocoagulation. After multidisciplinary counseling regarding limited pregnancy safety data and treatment alternatives, a single intravitreal faricimab injection was administered at 29 weeks and 6 days of gestation. One month later, left eye visual acuity improved from counting fingers to 20/25 with substantial clearance of the vitreous hemorrhage. Cesarean delivery was performed 37 days after injection at 36 weeks and 1 day of gestation for nonreassuring fetal heart tracings. No treatment-attributable adverse event was identified. To our knowledge, this represents the first reported use of intravitreal faricimab during pregnancy.

Oxford medical case reports 2026 Oct PubMed
04 Association Between Lipid Accumulation Product and Visceral Adiposity Index, as Markers of Visceral Adiposity and Metabolic Dysfunction, and Stroke: NHANES 1999-2018. Zhou Q et al. 10.1155/ije/6820633
View abstract

AIMS: Lipid accumulation product (LAP) and visceral adiposity index (VAI) are surrogate markers of visceral adiposity-related endocrine and metabolic dysfunction, including insulin resistance, rather than simple obesity indices. This study aimed to evaluate their associations with stroke prevalence using nationally representative data. MATERIALS AND METHODS: This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. Stroke status was determined through standardized questionnaires. LAP and VAI were calculated using established gender-specific formulas. Analyses used the fasting subsample weights with strata and primary sampling units, and missing covariates were multiply imputed. Weighted logistic regression, restricted cubic spline (RCS), subgroup and incremental discrimination analyses were performed. RESULTS: Among 21,146 participants, 721 reported a prior stroke (weighted prevalence 2.64%). Both indices were higher in stroke cases (median LAP 54 vs 42; VAI 1.72 vs 1.46, both < 0.001). In the primary model (Model 3), each 1-SD increment was associated with higher stroke odds for LAP (OR = 1.115, 95% CI 1.061-1.171, < 0.001) and VAI (OR = 1.073, 95% CI 1.020-1.129, = 0.007), and the highest quartile exceeded the lowest (LAP: OR = 1.557, 95% CI 1.117-2.170; VAI: OR = 1.381, 95% CI 1.026-1.858). Both were attenuated after additional adjustment for metabolic mediators (HbA1c, systolic blood pressure, eGFR and medication use), consistent with partial mediation. RCS analyses showed significant overall associations (LAP < 0.001; VAI = 0.041) without significant nonlinearity ( = 0.177 and 0.143). Only race/ethnicity modified the LAP-stroke association ( for interaction = 0.009; non-Hispanic Black OR = 1.427, 95% CI 1.231-1.654). Adding either index did not materially improve discrimination. CONCLUSIONS: Higher LAP and VAI values are associated with a greater prevalence of stroke after adjustment for demographic, socioeconomic, and lifestyle factors, and their attenuation after adjustment for metabolic variables is consistent with partial mediation through insulin resistance and its hemodynamic consequences. Both indices are inexpensive endocrine-metabolic markers of visceral adipose tissue dysfunction and insulin resistance that warrant prospective evaluation.

International journal of endocrinology 2026 PubMed
05 Adherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis. Ashour AM 10.2147/DMSO.S614243
View abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) requires sustained glycemic control to prevent long-term complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective therapies, traditionally administered via injection. The introduction of oral formulations, such as oral semaglutide, may improve patient adherence and persistence. METHODS: A systematic review with descriptive pooled synthesis was conducted using studies identified from PubMed, ClinicalTrials.gov, and relevant real-world observational data sources. Adherence and persistence outcomes were summarized and compared descriptively between injectable and oral GLP-1 RAs. RESULTS: Across the included total of 13 studies and medical records, data from 1348 patients were summarized. Oral GLP-1 RAs were associated with higher reported adherence (70.8% vs 62.4%) and persistence (62.1% vs 47.8%) compared with injectable formulations. A chi-square test of independence showed that the difference in adherence between oral and injectable GLP-1 was significant; ( = 10.8, p < 0.01). Similarly, chi-square test showed that the observed variation in persistence between Oral-GLP vs injectable GLP-1 was also significant ( = 37.9, p < 0.001). Injectable therapies were associated with higher rates of adverse events, particularly injection-site reactions. CONCLUSION: Oral GLP-1 RAs may be associated with improved adherence and persistence in patients with T2DM. These findings suggest that formulation choice may influence long-term diabetes treatment continuation, although further study-level meta-analytic research is needed.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
06 Multifactorial Contributors to Diagnostic Delay in a High-Risk Patient with Hepatocellular Carcinoma: A Case Report with Clinical Lessons. Hu J et al. 10.2147/IMCRJ.S638448
View abstract

BACKGROUND: Patients at high risk for primary liver cancer (PLC) are recommended to undergo PLC surveillance at least every six months. Alpha-fetoprotein (AFP) is a commonly used biomarker; however, approximately 15-30% of PLC cases remain AFP-negative throughout their course. Therefore, surveillance in high-risk populations should be based on liver imaging. Any newly detected or progressive lesion should be further characterized by contrast-enhanced computed tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or contrast-enhanced ultrasound, following guideline-based classification and follow-up recommendations. CASE PRESENTATION: This case details a 45-year-old Chinese male with hepatitis B virus (HBV) infection, type 2 diabetes mellitus, and a family history of PLC. As a high-risk individual for PLC, he did not undergo regular PLC surveillance for three years. During opportunistic encounters for acute myocardial infarction and abdominal pain, the attending specialists failed to appreciate the progression of liver imaging findings. In addition, the COVID-19 pandemic may have further aggravated pre-existing difficulties with follow-up and access to care, contributing to a delayed diagnosis of PLC. CONCLUSION: This case illustrates how a combination of physician-related, patient-related, and social-environmental factors contributed to surveillance failure and diagnostic delay in a high-risk patient with PLC. It reflects on why guideline-recommended interventions were not implemented at each healthcare encounter, how to correctly interpret AFP, and how to improve adherence to surveillance among high-risk populations for PLC. The insights from this case aim to inform systematic improvements in PLC monitoring for patients with chronic HBV infection.

International medical case reports journal 2026 PubMed
07 Meta-Analysis of the Impact of Low Glycemic Index Dietary Patterns on Blood Glucose Levels and Pregnancy Outcomes in Gestational Diabetes Mellitus. Zhang Y et al. 10.2147/DMSO.S599251
View abstract

OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the efficacy of low glycemic index (LGI) dietary patterns in improving glycemic control and pregnancy outcomes among patients with gestational diabetes mellitus (GDM). METHODS: Randomized controlled trials (RCTs) were identified through systematic searches of PubMed, The Cochrane Library, Web of Science, CNKI, VIP Medicine, Wanfang, and other relevant databases. Data extraction and quality assessment were conducted following Cochrane guidelines. Meta-analyses were performed using RevMan 5.3 and STATA 12.0 software. RESULTS: Eleven RCTs comprising 1209 participants were included. Compared with conventional diabetic diets, LGI dietary interventions significantly reduced fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin (HbA1c), and insulin resistance levels. Additionally, LGI diets were associated with a lower incidence of excessive gestational weight gain and improved neonatal outcomes. CONCLUSION: LGI dietary patterns effectively enhance glycemic control, mitigate insulin resistance, and improve perinatal outcomes in GDM patients. However, further high-quality studies with larger sample sizes are warranted to strengthen these conclusions.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
08 Type 2 diabetes mellitus and risk of incident peptic ulcer disease: a large-scale prospective cohort study. Wu Z et al. 10.1007/s40200-026-02106-z
View abstract

PURPOSE: Prospective evidence on the association between type 2 diabetes mellitus (T2DM) and incident peptic ulcer disease (PUD) remains limited, particularly after accounting for comorbidities and medications related to ulcer risk. We examined this association in the UK Biobank. METHODS: We analysed 344,612 participants, including 13,193 with T2DM at baseline, during up to 17.7 years of follow-up. Multivariable Cox proportional hazards models estimated associations of T2DM with incident PUD, gastric ulcer (GU), and duodenal ulcer (DU). RESULTS: Participants with T2DM had a higher cumulative incidence of PUD (log-rank  < 0.001). In the fully adjusted model, T2DM was associated with higher risks of PUD (hazard ratio [HR] 1.40, 95% confidence interval [CI] 1.27-1.54), GU (HR 1.34, 95% CI 1.19-1.51), and DU (HR 1.56, 95% CI 1.34-1.82). There was no evidence of interaction by regular pain medication use ( for interaction = 0.473). The associations were similar in three sensitivity analyses. CONCLUSION: Baseline T2DM was associated with a higher risk of incident PUD and its anatomical subtypes. Residual confounding, selection and detection biases, and the lack of systematic data preclude causal interpretation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02106-z.

Journal of diabetes and metabolic disorders 2026 Dec PubMed
09 Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework. Zhang J et al. 10.1007/s40265-026-02408-9
View abstract

Sarcopenia is increasingly recognised as a clinically important comorbidity in diabetes mellitus, particularly in older adults and individuals with long-standing type 2 diabetes. Because skeletal muscle is the principal site of insulin-stimulated glucose disposal, declines in muscle mass, quality, strength and physical performance may exacerbate insulin resistance and glycaemic instability and increase the risks of frailty, disability, falls, fractures, cardiovascular events and mortality. Contemporary glucose-lowering therapies have transformed diabetes care through established cardiorenal benefits and weight reduction, yet skeletal muscle outcomes are rarely prespecified or systematically assessed in pivotal trials. This evidence gap is especially relevant for weight-reducing agents such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, which are often associated with reductions in dual-energy X-ray absorptiometry-derived or bioelectrical impedance analysis-derived lean-mass estimates. However, these changes should be interpreted cautiously, as they often occur in the context of overall weight loss and may be influenced by alterations in body water. In addition, dual-energy X-ray absorptiometry- or dual-energy X-ray absorptiometry-derived lean-mass estimates do not directly quantify contractile skeletal muscle. Accordingly, reductions in lean-mass estimates alone are insufficient to infer clinically meaningful muscle loss without concurrent assessment of muscle strength or physical performance. This narrative review summarises the bidirectional mechanisms linking diabetes and sarcopenia and appraises major glucose-lowering drug classes from a muscle-centred perspective. It integrates mechanistic insights with human evidence on muscle-relevant outcomes, including body composition, strength and physical performance, and addresses practical safety and monitoring considerations in sarcopenia-prone phenotypes, including sarcopenic obesity. We also propose a pragmatic, hypothesis-generating Cardiorenal-Muscle Quadrant Framework that considers glycaemic efficacy and cardiorenal benefit alongside muscle reserve, functional status and treatment-related risks, with emphasis on functional monitoring, resistance exercise, nutritional optimisation and individualised glycaemic targets in older or frail adults.

Drugs 2026 Oct 17 PubMed
10 Prediabetes subtype-based stratification reveals distinct long-term risks for type 2 diabetes. Choe HJ et al. 10.1007/s00125-026-06866-4
View abstract

AIMS/HYPOTHESIS: Prediabetes is heterogeneous, with subtypes defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or HbA, each with different risks of progression to type 2 diabetes. We compared progression across these subtypes, and evaluated the benefit of adding insulin secretion and sensitivity to risk stratification. METHODS: We analysed 7186 Korean adults aged 40-69 years from the community-based Korean Genome and Epidemiology Study, who were followed for up to 20 years with biennial (every 2 years) oral glucose tolerance tests and HbA. Prediabetes was classified as IFG, IGT or HbA-defined, and further stratified by insulinogenic index (IGI) and insulin sensitivity index (ISI). Cox regression was used to estimate diabetes risk, and multistate Markov models were used to assess annual transition probabilities and time spent in each state. RESULTS: Compared with normoglycaemia, the adjusted hazard ratios (aHRs) were 5.84 (95% CI 5.03, 6.79) for IFG, 4.60 (95% CI 4.17, 5.07) for IGT, and 4.68 (95% CI 4.22, 5.19) for HbA-defined prediabetes. The risk increased stepwise with the number of criteria met: the aHRs were 3.10 (95% CI 2.81, 3.41) for one criterion, 7.33 (95% CI 6.50, 8.28) for two criteria, and 15.3 (95% CI 12.2, 19.3) for all three. Markov models showed the shortest prediabetes duration (1.7 years) and lowest regression probability (5.4%) in those meeting all three criteria. Low IGI or ISI predicted higher diabetes risk, and dual impairment conferred greatest risk (aHR 4.06; 95% CI 3.37, 4.90). Even normoglycaemic individuals with low IGI or ISI had an elevated risk of diabetes compared to those with high IGI or ISI. CONCLUSIONS/INTERPRETATION: Diabetes progression differs based on both glycaemic subtype and physiological subtype. Integrating IGI and ISI with conventional definitions enhances risk stratification and may help to identify high-risk individuals for earlier targeted intervention.

Diabetologia 2026 Oct 17 PubMed
11 Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study. Titus RS et al. 10.1016/j.urolonc.2026.09.012
View abstract

PURPOSE: Androgen deprivation therapy (ADT) is standard treatment for metastatic hormone-sensitive prostate cancer (mHSCaP). Patients receive LHRH-agonists (LHRH-AG: leuprolide, goserelin or triptorelin) or LHRH-antagonists (LHRH-AN: degarelix or relugolix) with intensification with androgen receptor pathway inhibitors, with or without chemotherapy. Given ongoing concerns about cardiovascular risk, we used real-world data from TriNetX to compare the incidence of major adverse cardiovascular events (MACE) between patients receiving LHRH-AG vs. LHRH-AN. MATERIALS AND METHODS: We included adult patients with mHSCaP who received either an LHRH-AG or LHRH-AN. The composite primary outcome was MACE (defined as myocardial infarction (MI), stroke, or all-cause mortality). Secondary outcomes were MI, stroke, and all-cause mortality. Patients were 1:1 propensity-score matched (PSM). Kaplan-Meier analysis reporting hazard ratios (HR) and 95% confidence intervals (CI) for the outcomes was conducted. We conducted a subgroup analysis to assess the effect of intensification of therapy. Exploratory analyses were conducted to assess HR of outcomes and new-onset metabolic comorbidities (diabetes mellitus, insulin use, hypertension, and dyslipidemia) amongst patients without cardiovascular risk factors. RESULTS: Before PSM, there were 27,051 in LHRH-AG and 3,339 in LHRH-AN cohorts. After PSM, 3,329 patients in each cohort were compared. Compared to LHRH-AN, LHRH-AG was associated with a decreased risk of MACE (hazard ratio [HR] = 0.86, 95% CI: 0.79-0.93), MI (HR = 0.80, 95% CI: 0.66-0.97), and any-cause mortality (HR = 0.85, 95% CI: 0.78-0.93). Treatment intensification did not modify the association between MACE outcomes and LHRH-AG vs. LHRH-AN. CONCLUSIONS: Using real-world data, LHRH-AG was associated with a decreased risk of experiencing MACE. Among those undergoing intensification of therapy, there was no difference in MACE risk associated with LHRH-AG vs. LHRH-AN.

Urologic oncology 2026 Oct 18 PubMed
12 Dapagliflozin alleviates CYH33-induced hyperglycemia and preserves antitumor immunity against ovarian cancer in type 1 diabetic mice. Sun J et al. 10.1016/j.lfs.2026.124743
View abstract

PI3K is frequently hyperactivated in ovarian cancer and has emerged as a promising therapeutic target. CYH33 is a novel PI3Kα-selective inhibitor that has been approved in Japan for the treatment of ovarian clear cell carcinoma harboring PIK3CA mutations. However, its on-target adverse effect of hyperglycemia limits its clinical application, particularly in patients susceptible to diabetes, underscoring the urgent need to optimize therapeutic strategies to improve both safety and efficacy. In this study, we employed an ID8 syngeneic murine ovarian cancer model and demonstrated that CYH33 significantly inhibited tumor growth with a modest effect on glucose homeostasis. We then established mouse models of type 1 (T1D) and type 2 diabetes (T2D) to expose hyperglycemia induced by PI3K inhibition and identified that dapagliflozin effectively alleviated CYH33-induced hyperglycemia while preserving its antitumor activity in T1D mice. Mechanistically, the combination of CYH33 and dapagliflozin may improve the immunosuppressive tumor microenvironment in T1D mice, as evidenced by upregulation gene sets involved in interferon-α and interferon-γ response, as well as significantly enhanced infiltration of CD8 T-cell in ID8 tumors. Furthermore, this combination synergized with anti-PD-1 antibody to further enhance antitumor efficacy. These findings provide a potential strategy for optimizing the clinical use of PI3K inhibitors and shed light on metabolic interventions to modulate tumor immune microenvironment.

Life sciences 2026 Oct 17 PubMed
13 Transition from pediatric to adult care for patients with type 1 diabetes mellitus: more than just a handover. Maltezou PG et al. 10.1016/j.eprac.2026.10.006
View abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease that commonly presents during childhood or adolescence and requires lifelong multidisciplinary care. The transition from pediatric to adult diabetes services is a pivotal stage often accompanied by poorer glycemic control, reduced clinic attendance, and increased risk of disengagement from healthcare. This review summarizes current evidence on the principles, challenges, and effective strategies for transitioning adolescents and young adults with T1D from pediatric to adult care. A review of the literature was conducted, focusing on transition models, clinical and psychosocial outcomes, and recommendations from the International Society for Pediatric and Adolescent Diabetes (ISPAD) and other relevant studies. Evidence supports transition as a structured, individualized, and developmentally appropriate process rather than a single transfer of care. Successful transition programs incorporate early preparation, multidisciplinary collaboration, joint pediatric-adult care, transition coordinators, psychosocial support, and progressive patient autonomy. These approaches improve continuity of care, self-management, clinic attendance, and glycemic outcomes while reducing loss to follow-up. Although transition care is increasingly recognized as a key component of T1D management, its implementation remains inconsistent. Wider adoption of standardized, evidence-based transition pathways is needed to optimize long-term health outcomes for young adults with T1D.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026 Oct 17 PubMed
14 Integrative m6A epitranscriptomic and transcriptomic analysis in livers of patients with type 2 diabetes mellitus. Chen Z et al. 10.1016/j.ygeno.2026.111327
View abstract

Type 2 diabetes mellitus (T2DM) is associated with hepatic metabolic remodeling, but the coordinated changes in N6-methyladenosine (m6A) modification and mRNA expression in human T2DM liver remain insufficiently defined. Here, we integrated mRNA expression profiles extracted from Arraystar Human LncRNA Microarray V5.0 with newly generated m6A epitranscriptomic microarray profiles in liver specimens from first-onset T2DM patients and controls. We identified 1923 differentially expressed and 7389 differentially m6A-methylated mRNA transcripts. Integrated analysis identified 898 dual-significant transcripts, predominated by hypermethylated-upregulated transcripts (n = 864), which were mainly enriched in amino acid, lipid, carbon, and energy metabolic pathways. By integrating m6A regulator expression, module-level correlation, and regulator-gene network connectivity, METTL14 was prioritized as a candidate component of the m6A writer complex associated with metabolic pathway remodeling. Ten METTL14-associated candidate genes were further prioritized, and clinical validation confirmed increased expression of METTL14 and most candidate genes in an independent human liver cohort. METTL14 depletion in Huh7 cells using two selected independent siRNAs concordantly reduced EHHADH, ACAT2, ACADS, SDHA, C3, and DLD. Secondary analysis of GSE185109 further showed significant downregulation of eight corresponding mouse orthologs in Mettl14-deficient liver, together with descriptive alterations in m6A peak patterns. These findings identify a functionally supported METTL14-associated m6A-mRNA network linked to hepatic metabolic remodeling in human T2DM, while direct transcript-specific m6A regulation remains to be established.

Genomics 2026 Oct 17 PubMed
15 C-reactive protein-albumin-lymphocyte index and coronary microvascular dysfunction after primary percutaneous coronary intervention: The mediating role of insulin resistance. Wang W et al. 10.1016/j.ijcard.2026.135001
View abstract

BACKGROUND: The C-reactive protein-albumin-lymphocyte (CALLY) index integrates systemic inflammation, nutritional status, and immune function. We investigated its association with angiography-derived microvascular resistance (AMR)-defined coronary microvascular dysfunction (CMD) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), and performed an exploratory statistical mediation analysis involving estimated glucose disposal rate (eGDR). METHODS: This retrospective, single-center observational study included 456 consecutive patients with STEMI undergoing primary PCI. AMR-defined CMD was prespecified as AMR ≥250 mmHg·s/m. Multivariable logistic regression, restricted cubic spline (RCS), and prespecified subgroup analyses were performed. Sensitivity and exploratory mediation analyses were also performed. RESULTS: AMR-defined CMD was present in 228 patients (50.0%). In Model 3, each doubling of CALLY was associated with lower odds of AMR-defined CMD (OR, 0.87; 95% CI, 0.80-0.94; P < 0.001). Compared with Q1, Q3 and Q4 were associated with 44% (OR, 0.56; 95% CI, 0.32-0.97; P = 0.037) and 52% (OR, 0.48; 95% CI, 0.28-0.84; P = 0.010) lower odds, respectively (P for trend = 0.018). RCS analysis showed an overall association (P = 0.001) without evidence of nonlinearity (P = 0.310). No significant subgroup interactions were observed. Exploratory mediation analysis estimated that eGDR statistically accounted for 15.47% of the observed association. CONCLUSIONS: Higher CALLY values were inversely associated with AMR-defined CMD after primary PCI for STEMI. eGDR may account for part of this association. CALLY may serve as an auxiliary marker for AMR-defined CMD risk stratification, pending prospective multicenter validation.

International journal of cardiology 2026 Oct 17 PubMed
16 Nicotinamide mononucleotide supplementation improves polycystic ovary syndrome by activating silent regulatory protein 2 mediated lactate dehydrogenase A lysine 119 deacetylation to enhance glycolytic activity. Zhang Z et al. 10.1016/j.ijbiomac.2026.154894
View abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with impaired granulosa cell (GC) glycolytic activity. Although lactate dehydrogenase A (LDHA)-a key glycolytic enzyme modulated by acetylation-is involved, its regulatory mechanism remains unclear. This study investigated whether nicotinamide mononucleotide (NMN) alleviates PCOS by promoting LDHA deacetylation to enhance glycolytic function. METHODS: We established a PCOS rat model via letrozole (1 mg/kg/d) gavage combined with high-fat diet for 30 days; after successful modeling, rats were randomly assigned to receive either vehicle or NMN (500 mg/kg/d) for an additional 30 days..We then evaluated metabolic phenotypes, reproductive hormone profiles, ovarian histopathology, and estrous cycle regularity. The underlying molecular mechanism was verified in testosterone (10 μM)-treated human granulosa-like KGN cells via a series of molecular assays including qRT-PCR, western blotting, co-immunoprecipitation (Co-IP), and site-directed mutagenesis. RESULTS: NMN supplementation significantly reversed insulin resistance, hyperandrogenism, estrous cycle disorder, and polycystic ovarian morphology in PCOS rats, and simultaneously increased ovarian NAD levels and glycolytic activity. We further identified SIRT2 as the specific deacetylase of LDHA, and uncovered K119 as the key functional acetylation site that regulates LDHA enzymatic activity. Mechanistically, NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs. CONCLUSION: Our findings demonstrate that NMN enhances glycolytic activity in ovarian GCs via the SIRT2/LDHA-K119 regulatory axis, thereby ameliorating PCOS-related reproductive and metabolic disorders. Collectively, these findings identify the SIRT2-LDHA axis as a novel therapeutic target and provide preclinical evidence supporting NMN as a potential intervention for PCOS.

International journal of biological macromolecules 2026 Oct 17 PubMed
17 Validation studies of ICD-10 diagnostic codes for identifying common causes of hospitalization: a scoping review. Henderson HI et al. 10.1016/j.jclinepi.2026.112570
View abstract

BACKGROUND: International Classification of Diseases, Tenth Revision (ICD-10) diagnosis codes are widely used to identify clinical conditions in administrative health data for epidemiologic research, surveillance, and health services evaluation. However, the validity of ICD-10-coded diagnoses varies across conditions and healthcare settings, and validation studies differ substantially in design, case definitions, and reporting practices. OBJECTIVE: To characterize validation studies of ICD-10-based case definitions for eight common causes of hospitalization and identify methodological factors affecting the interpretation and comparability of reported performance estimates. DESIGN: PubMed and Embase (2005-2025) were searched for systematic reviews and primary studies validating ICD-10-coded diagnoses for the following conditions: heart failure, osteoarthritis, pneumonia, diabetes mellitus, acute myocardial infarction, chronic obstructive pulmonary disease, acute kidney injury, and stroke. Data on study characteristics, case definitions, reference standards, and performance metrics were extracted and descriptively summarized. RESULTS: We identified 116 unique primary publications through 11 systematic reviews and our database search. Stroke and heart failure had the largest evidence base, whereas few validation studies were identified for several conditions. More than one-third of studies reported only positive predictive value, typically reflecting a study design that verified algorithm-identified cases and therefore precluded estimation of sensitivity and specificity. When reported, specificity was generally high, whereas sensitivity varied considerably; however, differences in study design limited comparability of estimates. Incorporating laboratory results, procedures, medications, or other electronic health record data often improved the performance of ICD-10-based case definitions. CONCLUSIONS: Validation studies of ICD-10-coded diagnoses are highly heterogeneous in design and reporting, limiting direct comparison across studies. Many rely on designs that only estimate positive predictive value and therefore provide incomplete assessments of validity. Standardized, population-based validation studies measuring both sensitivity and specificity are needed to improve the reliability and reproducibility of administrative health data for epidemiologic research, surveillance, and quality improvement.

Journal of clinical epidemiology 2026 Oct 17 PubMed
18 AI-derived panoramic score and its association with major systemic diseases: A retrospective cross-sectional study. Kahm SH et al. 10.1016/j.jdent.2026.107104
View abstract

OBJECTIVES: This study evaluated whether an AI-generated, panoramic radiograph-based score was associated with five selected systemic diseases. METHODS: 26,550 panoramic radiographs from two hospitals were analyzed using an AI model that detected teeth and implants and quantified alveolar bone loss. A radiograph-based score (0-100) was derived from missing teeth and weighted bone-loss severity. Associations with diabetes mellitus, hypertension, osteoporosis, ischemic heart disease, and hyperlipidemia were assessed using between-group comparisons, prevalence trends across score bins, and logistic regression adjusted for age, sex, and body mass index. Incremental discrimination over covariates alone was quantified using ΔAUC and the DeLong test. RESULTS: Patients with each condition had lower scores than controls (all P<0.001), with the largest adjusted difference for diabetes mellitus (β=-6.25). Prevalence of all five conditions showed a decreasing trend across ascending score strata (Cochran-Armitage P<0.001), with the highest Q1-to-Q5 relative risk for ischemic heart disease (4.73). After adjustment, the score remained independently associated with all diseases (AUC, 0.74-0.80), with significant incremental discrimination for diabetes mellitus, hypertension, and hyperlipidemia (ΔAUC =0.0015-0.0154; DeLong P<0.0188) but not ischemic heart disease or osteoporosis. CONCLUSIONS: An AI-derived panoramic radiograph-based score was independently associated with five selected systemic diagnoses. Clinical significance An AI-derived score obtained from routinely acquired panoramic radiographs was independently associated with major systemic diseases. This automated, quantitative score may serve as an exploratory image-based index, supporting integrated management between dental and medical care.

Journal of dentistry 2026 Oct 17 PubMed
19 Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH). Sanyal AJ et al. 10.1016/j.jhepr.2026.102068
View abstract

BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with limited treatment options. Fazpilodemab, a bispecific antibody targeting fibroblast growth factor receptor 1 (FGFR1) and Klotho β (KLB), showed promising trends in liver health markers in type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. METHODS: This Phase 2 randomized study evaluated the efficacy, safety, and pharmacokinetics of fazpilodemab in patients with MASH and hepatic steatosis. Patients were randomized to receive fazpilodemab or placebo subcutaneously every 2 weeks for 52 weeks. The primary endpoint was MASH resolution without fibrosis worsening at Week 52. Secondary endpoints included histological improvement from baseline (≥2 points reduction in MAS with ≥ 1-point reduction in either lobular inflammation or hepatocellular ballooning and no worsening of fibrosis stage), fibrosis improvement from baseline (≥1 MASH CRN fibrosis stage) and no worsening of steatohepatitis (no increase in MAS for ballooning, inflammation, or steatosis), and changes in hepatic fat fraction. Safety, PK, and immunogenicity were also assessed. RESULTS: A total of 46 patients (fazpilodemab 50 mg [n=11], 75 mg [n=11], or 100 mg [n=11]; and placebo [n=13]) were enrolled, of whom 23 had Week 52 or early termination biopsy. The proportion of patients achieving resolution of MASH without worsening of fibrosis was 37.5% (3/8) in the 50 mg arm, 14.3% (1/7) in the 75 mg arm, and 33.3% (2/6) in the 100 mg arm, compared to 16.7% (1/6) in the placebo arm. For the secondary endpoints, improvements in liver histology and fibrosis were numerically higher in fazpilodemab-treated patients; transient improvements in hepatic fat fraction were observed. Fazpilodemab was adequately tolerated, with no new safety signals identified. CONCLUSIONS: While the study was prematurely terminated, fazpilodemab demonstrated a safety profile consistent with previous studies. No definite conclusion could be drawn regarding the preliminary fazpilodemab efficacy profile due to the limited sample size and early dropouts. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04171765 IMPACT AND IMPLICATIONS: Dual targeting of FGFR1 and Klotho β (KLB) with fazpilodemab demonstrated preliminary signals in liver histology and steatosis reduction alongside a favorable safety profile in patients with MASH. Although early trial termination precludes definitive efficacy conclusions, these findings support FGFR1 agonism as a viable strategy for future drug development in metabolic liver disease.

JHEP reports : innovation in hepatology 2026 Oct 17 PubMed
20 Comparative effectiveness of turmeric and curcumin formulations on glycemic, lipid, and inflammatory markers in people with prediabetes: A systematic review and network meta-analysis. Khongphakdee P et al. 10.1016/j.ctim.2026.103453
View abstract

Prediabetes is a growing global health concern associated with higher risk of diabetes and cardiovascular disease. Curcumin has been studied for glycemic, lipid, and inflammatory effects, but comparative data across formulations remain limited. This network meta-analysis (NMA) evaluated turmeric and curcumin formulations in adults with prediabetes. Seven databases were searched for randomized controlled trials (RCTs) comparing turmeric/curcumin formulations with placebo. Primary outcomes included glycemic, lipid, and inflammatory markers. Two reviewers independently extracted data and assessed risk of bias. NMAs with surface under the cumulative ranking curve (SUCRA) were performed. Twenty-four RCTs (25 publications, 1,952 participants; mean baseline fasting blood sugar (FBS): 110.3mg/dL) evaluating eight curcumin-based formulations were included. Turmeric extract combined with other compounds (EC) and turmeric extract (E) were associated with significant reductions in FBS with WMD -10.73 (95%CI: -14.22, -7.25;SUCRA 92.2%), and -10.57 (95%CI: -14.35, -6.79;91.5%;SUCRA 91.5%), respectively. E was associated with a significant reduction in HbA1c, while EC was associated with lower HOMA-IR with MWD -0.73 (95%CI: -1.41, -0.05; SUCRA 79.8%). Whole turmeric with other compounds (WC) was associated with a significant reduction in LDL-C (WMD: -37.19, 95%CI: -56.97, -17.42; SUCRA: 97.3%). E was associated with a lower risk of incident type 2 diabetes (RR= 0.05; 95%CI:0.00,0.78), although this estimate was based on low-certainty of evidence. No significant effects were observed for inflammatory markers. Overall certainty of evidence was low due to heterogeneity and short trial durations, and variability among combination formulations. In prediabetes, formulation-specific metabolic effects were observed. However, given the low certainty of evidence, these findings should be interpreted cautiously and confirmed in larger, longer-term trials before clinical recommendation can be made.

Complementary therapies in medicine 2026 Oct 17 PubMed
21 Poria cocos triterpenes alleviate diabetes mellitus by regulating the gut microbiota-barrier-inflammation axis and inhibiting the TLR4/nF-κB/NLRP3 pathway. Zhao B et al. 10.1080/14786419.2026.2746484
View abstract

Diabetes mellitus (DM) is a chronic metabolic disorder characterised by progression associated with dysregulation of gut immunity and impairment of the intestinal barrier. triterpenes (PCT) exhibit hypoglycaemic effects; however, the mechanisms underlying these effects remain inadequately elucidated. We aimed to investigate the anti-diabetic properties of PCT. The findings revealed the identification of 60 PCT components, with 35 being absorbed into the serum of diabetic rats. PCT administration resulted in a significant reduction in blood glucose and lipid levels, restoration of gut microbiota homeostasis, and enhancement of intestinal barrier integrity through the upregulation of ZO-1 and occludin. PCT inhibited the TLR4/NF-κB/NLRP3 pathway and modulated metabolites, such as those involved in tryptophan metabolism, which were correlated with changes in the microbiota. These results suggest that PCT mitigates DM via the gut microbiota-barrier-inflammation axis, underscoring its potential for diabetes management and the integration of medicinal fungi into interventions for metabolic diseases.

Natural product research 2026 Oct 17 PubMed
22 Quantitative assessment of foot microcirculation by CT perfusion differentiates chronic limb-threatening ischemia from claudication in peripheral artery disease. Du S et al. 10.1177/1358863X261470372
View abstract

INTRODUCTION: Computed tomography perfusion (CTP) is validated to assess foot microcirculatory perfusion in peripheral artery disease (PAD). This study aimed to investigate differences in foot microcirculation on CTP between patients with claudication (Cla) and chronic limb-threatening ischemia (CLTI) and to develop diagnostic models for CLTI. METHODS: This single-center prospective study enrolled hospitalized patients with PAD at Huadong Hospital, China (October 2022 to January 2024). Participants underwent preoperative foot CTP and were stratified into Cla (Rutherford category 3) and CLTI (Rutherford categories 4-6) groups. Baseline characteristics and perfusion parameters were recorded. Multivariable logistic regression and receiver operating characteristic curve analysis were performed. RESULTS: A total of 57 patients with PAD were included (34 Cla, 23 CLTI). Resting ankle-brachial index and Global Limb Anatomic Staging System scores did not differ significantly between groups. Diabetes mellitus (DM) prevalence was higher in the CLTI group (95.7% vs 52.9%; = 0.002). Multivariable logistic regression identified hemoglobin (Hb) level (OR, 0.91; 95% CI, 0.822-0.986; = 0.024), time to peak (TTP) (OR, 1.135; 95% CI, 1.045-1.250; = 0.003), and blood flow (BF) (OR, 0.668; 95% CI, 0.499-0.894; = 0.007) as independent predictors for CLTI. Four diagnostic models were constructed: model A (BF + DM, area under the curve [AUC] 0.864), model B (BF + Hb, AUC 0.890), model C (TTP + DM, AUC 0.895), and model D (TTP + Hb, AUC 0.874). CONCLUSION: Foot microcirculation differed significantly between patients with Cla and CLTI on CTP. Hb, TTP, and BF were independent predictors for CLTI. All models demonstrated good diagnostic performance, with model C yielding the highest AUC. CLINICALTRIALS: gov Identifier:NCT05575778.

Vascular medicine (London, England) 2026 Oct 17 PubMed
23 From genotype to phenotype: reverse phenotyping of a novel INSR variant in a large family with hyperinsulinemic hypoglycemia. Soltanova L et al. 10.1007/s13353-026-01121-3
View abstract

The insulin receptor gene (INSR) encodes a ligand-activated tyrosine kinase that plays a central role in glucose homeostasis. Pathogenic variants in INSR are associated with a spectrum of insulin resistance syndromes. Here we report a novel INSR variant in a large multigenerational family. A 53-year-old woman presented to the endocrinology clinic with recurrent hypoglycemic episodes. Exome sequencing was performed for the index case, and variant segregation analysis was conducted in family members by Sanger sequencing. Genetic testing revealed a likely pathogenic variant in exon 19 of the INSR gene, NM_000208.4:c.3473G > C,p.(Arg1158Pro). Segregation analysis identified eight heterozygous carriers among thirteen tested family members. Reverse phenotyping revealed recurrent hyperinsulinemic hypoglycemia. Affected individuals demonstrated normal body mass index, low adiposity, and preserved fat-free mass, distinguishing this phenotype from classical insulin-resistance syndromes. Female carriers frequently exhibited hyperandrogenic features including hirsutism, menstrual irregularities, and acanthosis nigricans. These findings expand the clinical spectrum of INSR-related disorders and highlight the importance of considering INSR variants in patients with familial hyperinsulinemic hypoglycemia, particularly when clinical features mimic insulinoma.

Journal of applied genetics 2026 Oct 17 PubMed
24 Relative muscle mass and grip strength as complementary correlates of metabolic syndrome: a nationwide DXA-based study of Korean adults. Lee EY et al. 10.1007/s12020-026-04804-3
View abstract

PURPOSE: Both muscle mass and strength relate to metabolic health, but their separate contributions to metabolic syndrome (MetS) are unclear. Using the 2024 Korea National Health and Nutrition Examination Survey (KNHANES) with concurrent dual-energy X-ray absorptiometry (DXA)-based appendicular skeletal muscle mass (ASM) and handgrip strength (HGS), we examined the independent associations of relative muscle mass and HGS with MetS in Korean adults aged ≥40 years. METHODS: We analyzed 3033 adults from KNHANES. ASM/body weight (ASM/BW) and HGS/body weight (relative HGS) served as primary indicators. Participants were classified into four groups by sex-specific medians of both indicators, and complex-sample logistic regression estimated odds ratios (ORs) for MetS with both indicators entered simultaneously. RESULTS: In the fully adjusted joint model, ASM/BW was inversely associated with MetS in men (OR 0.79, 95% CI 0.73-0.86) and women (OR 0.86, 0.80-0.92), as was relative HGS (men OR 0.98, 0.96-0.99; women OR 0.97, 0.95-0.98). The odds of MetS were highest with concurrently low muscle mass and strength (men OR 3.04; women OR 2.42). The ASM/BW association persisted when MetS was defined without the waist criterion, whereas the relative HGS association was attenuated; ASM/BMI showed similar inverse associations, whereas ASM/Ht² showed a different pattern. CONCLUSION: ASM/BW showed more consistent associations with MetS across the sensitivity analyses performed than relative HGS, although associations differed by normalization method, the optimal choice of which remains uncertain. Because the design is cross-sectional, these findings indicate association only and require prospective validation before clinical application.

Endocrine 2026 Oct 17 PubMed
25 Periconceptional and early-pregnancy exposure to SGLT2 inhibitors and congenital malformations: a systematic review and meta-analysis. Dutta D et al. 10.1007/s12020-026-04839-6
View abstract

PURPOSE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly prescribed to women of reproductive age for type 2 diabetes and cardiorenal protection, and are commonly continued through the periconceptional period until pregnancy is recognized. Human safety data on inadvertent first-trimester exposure remain scarce, creating substantial clinical uncertainty. METHODS: We systematically searched PubMed/MEDLINE, Embase, and CENTRAL from inception to 15 May 2026 for observational cohort studies comparing early-pregnancy or preconception exposure to SGLT2 inhibitors with active antidiabetic comparators among women with type 2 diabetes. Adjusted risk ratios (RRs) were pooled using random-effects meta-analysis. RESULTS: Three cohorts, including 669 SGLT2 inhibitor-exposed pregnancies, were eligible. In the prespecified insulin-comparator analysis, SGLT2 inhibitor exposure was not associated with major congenital malformations (RR 0.94, 95% CI 0.68-1.29) or cardiac malformations (RR 0.97, 95% CI 0.64-1.48). The inclusion of a preconception sulfonylurea comparator cohort yielded a similar estimate for major congenital malformations (RR 0.98, 95% CI 0.74-1.29). In a Korean cohort, exposure during gestational weeks 4-10 was associated with congenital heart defects (RR 2.79, 95% CI 1.16-7.06). CONCLUSIONS: Based on the limited observational evidence available, early SGLT2 inhibitor exposure was not associated with an increased risk of overall major congenital or cardiac malformations; however, the estimates were imprecise and could not rule out clinically important increases in risk. Certainty of the evidence was low to very low because of residual confounding, live-birth selection, heterogeneous exposure definitions, and few exposed events. A possible timing-specific cardiac signal requires replication.

Endocrine 2026 Oct 17 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Diabetes (Type 2)
  • Week: October 12 – October 19, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 7:49 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —